Longitudinal study on the epidemiology and management of auto-immune thrombocytopenia (AITP) in Algeria

Study identification

• PURI:
  https://redirect.ema.europa.eu/resource/36269
• EU PAS number:
  EUPAS20687
• Study ID:
  36269
• Official title and acronym:
  Longitudinal study on the epidemiology and management of auto-immune thrombocytopenia (AITP) in Algeria
• DARWIN EU® study:
  No
• Study countries:
  Algeria
• Study description:
  Epidemiological, national, prospective, longitudinal study about the management of patients with auto-immune thrombocytopenia followed up by hematologists in the public sector in Algeria.
• Study status:
  Finalised

Research institutions and networks

Institutions

Amgen

United States

Multiple centres: 16 centres are involved in the study

Study timelines

Date when funding contract was signed

Planned: 07/04/2017

Actual: 07/07/2017

Study start date

Planned: 08/09/2017

Actual: 08/09/2017

Data analysis start date

Planned: 31/07/2019

Actual: 14/07/2019

Date of final study report

Planned: 30/06/2020

Actual: 09/07/2020

Sources of funding

Pharmaceutical company and other private sector 

More details on funding

Amgen

Study protocol

Initial protocol

20160214_01.02.06 Public Redacted Protocol Ver 1.0 2018-07-28 English

Regulatory

• Was the study required by a regulatory body?:
  No
• Is the study required by a Risk Management Plan (RMP)?:
  Not applicable